Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 2Completed 1

Sponsor Class

INDUSTRY 281OTHER 167NIH 24NETWORK 6OTHER_GOV 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 20Breast 6Tumor-Agnostic 3Thoracic 3Gynecologic 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 89Lung Neoplasms 78Small Cell Lung Carcinoma 28Adenocarcinoma of Lung 8Mesothelioma, Malignant 6Esophageal Neoplasms 6Carcinoma, Hepatocellular 4Adenocarcinoma 4Stomach Neoplasms 3Neoplasm Metastasis 3NSCLC 3Motor Activity 3Mesothelioma 3Meningeal Carcinomatosis 3Carcinoma, Renal Cell 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Thymoma 2Sarcopenia 2Pancreatic Neoplasms 2Neuroendocrine Tumors 2Neoplasms 2Melanoma 2Lung Diseases 2EGFR Positive Non-small Cell Lung Cancer 2Disease 2Colorectal Neoplasms 2Weight Loss 1Untreated Advanced Non-small Cell Lung Cancer 1Unresectable Non-small Cell Lung Cancer 1

Interventions

Temozolomide 1Talc 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER_GOV × Neoplasm Metastasis × Thoracic × Clear all
NCT00821860 2013-06-28

MesoVATS

Papworth Hospital NHS Foundation Trust

Phase 3 Completed
196 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Neoplasm Metastasis, Pleural Effusion, Malignant, Solitary Fibrous Tumor, Pleural

NCT00862173 2012-06-12

Gene-expression Profiles in CNS-metastatic Non-small Cell Lung Cancer

National Institute of Cancerología

Unknown
120 enrolled
Thoracic

Brain Diseases, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT00268684 2006-02-28

Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC

Tel-Aviv Sourasky Medical Center

Phase 3 Unknown
381 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡